TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04485000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online 1-Day Cognitive Behavioural Therapy (CBT)-Based Workshop
Description: The workshop is a day-long intervention delivered in 4 modules based on Cognitive Behavioural Therapy (CBT). The workshop covers PPD etiology, modifiable cognitive risk factors, cognitive skills, behavioural skills, problem solving, goal setting and action planning. Each participant is given a professionally designed manual to facilitate learning. Weekly reminder emails are sent for 6 weeks after the workshop completion to encourage practice. A list of PPD resources and a copy of the Canadian Treatment Guidelines for Postpartum Depression are provided.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Online 1-Day Cognitive Behavioural Therapy (CBT)-Based Workshop
Description: The workshop is a day-long intervention delivered in 4 modules based on Cognitive Behavioural Therapy (CBT). The workshop covers PPD etiology, modifiable cognitive risk factors, cognitive skills, behavioural skills, problem solving, goal setting and action planning. Each participant is given a professionally designed manual to facilitate learning. Weekly reminder emails are sent for 6 weeks after the workshop completion to encourage practice. A list of PPD resources and a copy of the Canadian Treatment Guidelines for Postpartum Depression are provided.
Study: NCT04647344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104 plus Carboplatin and Pemetrexed
Description: Subjects receive AK104 15mg/kg intravenously (IV) plus pemetrexed 500 mg/m\^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK104 15mg/kg IV plus pemetrexed 500 mg/m\^2 IV Q3W until progression.
Study: NCT01114802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Onward website + social network
Description: The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project Onward website
Description: Access to an interactive website that provides 8 weeks of Internet-based cognitive behavioral therapy.
Study: NCT04647344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104 plus Carboplatin and paclitaxel
Description: Subjects receive AK104 15mg/kg intravenously (IV) plus paclitaxel 175 mg/m\^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK104 15mg/kg IV IV Q3W until progression.
Study: NCT02371083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extended timing of pessary care
Study: NCT02429869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study: NCT04310826

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Receive dietary magnesium intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Undergo video interviews

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive phone calls
Study: NCT02445612

Intervention type: BIOLOGICAL
Intervention: MA09-hRPE
Description: Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
Study: NCT04179539

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: V/Q PET/CT
Description: Ventilation images are acquired after inhalation of Galligas prepared using a Technegas generator (Cyclopharm, Sydney, Australia). The patients is placed in a supine position and inhaled Galligas using the standard ventilation technique. Ventilation images are then acquired. Without the patient moving, 68Ga-MAA are then injected. Perfusion PET images are then acquired

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CTPA
Description: CTPA will be done according to the usual protocol in the radiology department of the investigator center
Study: NCT01759381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Study: NCT03873519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chromatic Environment
Description: Rooms where chemotherapy sessions are delivered will be modified to show warm/cold color temperature in walls and equipment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chromatic Environment
Description: Rooms where chemotherapy sessions are delivered will be modified to show warm/cold color temperature in walls and equipment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chromatic Environment
Description: Rooms where chemotherapy sessions are delivered will be modified to show warm/cold color temperature in walls and equipment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chromatic Environment
Description: Rooms where chemotherapy sessions are delivered will be modified to show warm/cold color temperature in walls and equipment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Room Orientation
Description: Room will be facing North or South

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Room Orientation
Description: Room will be facing North or South

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Room Orientation
Description: Room will be facing North or South

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Room Orientation
Description: Room will be facing North or South
Study: NCT03833388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOP1630 0.1% Ophthalmic Solution TID OU
Description: Bilateral ocular drug administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to TOP1630 0.1% Ophthalmic Solution TID OU
Description: Bilateral ocular drug administration
Study: NCT01766011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: study pre-term formula
Description: 24 kcal/fl oz pre-term formula for in-hospital use
Study: NCT03387371

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonics
Description: ultrasonic scalers

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gracey Curettes
Description: Spesific gracey curettes
Study: NCT02532010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pacritinib
Description: Pacritinib is a novel Janus kinase 2-fms-like receptor tyrosine kinase 3 (JAK2-FLT3) inhibitor that has shown promising antitumor activity. Pacritinib is a potent inhibitor of JAK2 and FLT3 kinase activities (50% inhibitory concentration (IC50) = 23 nanomolar (nM)and 22 nM, respectively). The drug also inhibits cellular proliferation in human leukemia and lymphoma cell lines selected for their dependence on either of the target kinases. Consistent with these activities, exposure to pacritinib resulted in the reduction of phos-JAK2, phos-STAT3 or phos-STAT5 in the relevant cell lines. Unlike some JAK2 inhibitors, pacritinib does not inhibit Janus kinase 1 (JAK1).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pacritinib
Description: Pacritinib is a novel Janus kinase 2-fms-like receptor tyrosine kinase 3 (JAK2-FLT3) inhibitor that has shown promising antitumor activity. Pacritinib is a potent inhibitor of JAK2 and FLT3 kinase activities (50% inhibitory concentration (IC50) = 23 nanomolar (nM)and 22 nM, respectively). The drug also inhibits cellular proliferation in human leukemia and lymphoma cell lines selected for their dependence on either of the target kinases. Consistent with these activities, exposure to pacritinib resulted in the reduction of phos-JAK2, phos-STAT3 or phos-STAT5 in the relevant cell lines. Unlike some JAK2 inhibitors, pacritinib does not inhibit Janus kinase 1 (JAK1).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: Commercial drug: For each cycle Decitabine 20mg/m2 intravenous daily for 10 days combined with ongoing pacritinib 200 mg twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Commercial drug: For each cycle Cytarabine 20mg subcutaneous twice daily for 10 days combined with ongoing pacritinib 200mg twice daily.
Study: NCT03387371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gracey Curettes
Description: Spesific gracey curettes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG Laser
Description: 2940 nm wavelenght Er:YAG laser
Study: NCT01230086

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICD Implantation without DFT testing
Description: Implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Upper limit of vulnerability testing
Description: Upper limit of vulnerability testing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T-wave shock with induction of ventricular fibrillation
Description: Traditional safety margin testing for defibrillation threshold

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T-wave shock with induction of ventricular fibrillation
Description: Traditional safety margin testing for defibrillation threshold
Study: NCT01411150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate
Description: Up to 30 grams daily creatine monohydrate
Study: NCT03907475

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study: NCT01523782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRASPA
Description: Each patient will receive GRASPA at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRASPA
Description: Each patient will receive GRASPA at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRASPA
Description: Each patient will receive GRASPA at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
Study: NCT05442502

Intervention type: PROCEDURE
Intervention: The overlap guiding tube(OGT) method
Description: The overlap guiding tube(OGT) is used to assist the anvil fork placed into the esophageal cavity.

Intervention type: PROCEDURE
Intervention: The conventional overlap method
Description: After firing the stapler, two openings were converted into a single entry hole to create an end-to-side esophagojejunostomy, and the entry hole was closed with full-thickness running suture using barbed sutures intracorporeally.
Study: NCT04445272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Treatment with Tocilizumab
Study: NCT04504448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNC664 capsules Single dose
Description: HNC664 capsules,single ascending doses Single dose, PO,starting dose of 40mg escalating up to 500mg
Study: NCT01402115

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polycan
Description: polycan 150 mg/d for 12 weeks
Study: NCT04504448

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HNC664 placebos Single dose
Description: HNC664 placebos single ascending doses,PO,Single dose, matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNC664 capsules FED
Description: HNC664 capsules,single doses Single dose, PO,food effect（dosage will be based on data from SAD cohorts and decided by the IDRC）
Study: NCT03377231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stratamark®
Description: Film-forming dressing for the prevention and treatment of stretch marks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stratamark®
Description: Film-forming dressing for the prevention and treatment of stretch marks.
Study: NCT03193853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tak-228 & Tak-117
Description: Patients will receive 4mg oral TAK-228 and 200mg TAK-117 tablets until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin & Nab Paclitaxel
Description: following Tak-228 \& Tak-117 standard nab paclitaxel 175-220 mg/m2 plus cisplatin 60-75 mg/m2 infusion for six cycles. Patients who did not progress may continue nab paclitaxel under treating physicians discretion
Study: NCT03498430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (Aliqopa, BAY80-6946)
Description: Copanlisib will be administered intravenously on 60mg once in a 3 weeks-on/1 week-off dose regimen (on Days 1, 8 and 15)
Study: NCT03853174

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance Training ET
Description: Endurance training were prformed. Intensity was gradually increased.

Intervention type: OTHER
Group type: OTHER
Intervention: Resistance Training RT
Description: Resistance training were prformed. Intensity was gradually increased.
Study: NCT01315938

Intervention type: DRUG
Group type: OTHER
Intervention: Abatacept Active Treatment
Description: Participants will be treated with abatacept by intravenous infusions a total of seven times at week(s) 0, 2, 4, 8, 12, 16 and 20 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Abatacept Delayed-Onset Treatment
Description: Participants will be treated with abatacept for 6 months and received a total of seven intravenous infusions at weeks 12, 14, 16, 20, 24, 28 and 32.
Study: NCT03742518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical SM04554 solution
Description: Study medication application will be performed by the individual subject at approximately the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical SM04554 solution
Description: Study medication application will be performed by the individual subject at approximately the same time each day.
Study: NCT01402115

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 150mg/d for 12 weeks
Study: NCT01478503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron OCAS
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT03742518

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical vehicle solution
Description: Vehicle solution application will be performed by the individual subject at approximately the same time each day.
Study: NCT00439764

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General health talk
Description: Routine clinical practice and talk on general health

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Handout of The Back Book
Description: Talk on health of the back and handout of The Back Book

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Handout of The Back Book
Description: Talk on health of the back and handout of The Back Book

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Back exercise
Description: Routine clinical practice, talk on back health, handout of The Back Book and back exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Back exercise
Description: Routine clinical practice, talk on back health, handout of The Back Book and back exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Back exercise
Description: Routine clinical practice, talk on back health, handout of The Back Book and back exercise
Study: NCT02223962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Counseling about physical activity will only be provided in the intervention group by 3 weekly telephone contacts. Based on the information the physiotherapist receives, he or she will adapt the goal (in agreement with the patient) and motivate the patient to reach the individual goal.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical activity
Description: Counseling about physical activity will only be provided in the intervention group by 3 weekly telephone contacts. Based on the information the physiotherapist receives, he or she will adapt the goal (in agreement with the patient) and motivate the patient to reach the individual goal.
Study: NCT00053196

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: 2.5mg/kg/day IV infusion over 6 hrs x 4 doses Days -4 to -1 (for MUD and 9/10 related donor transplants only)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 ug/kg/day subQ injection Day 7 until ANC\> 1000/uL for 3 consec days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: 0.8mg/kg IV infusion over 2 hrs q 6 hrs x 8 doses Days -4 thru -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 30 mg/sq m/day IVBP over 30 min Days -7 thru -3
Study: NCT04390139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XCEL-UMC-BETA
Description: Administration on top of the standard administered treatment
Study: NCT00053196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 5 mg/sq m/day IV infusion Days 1, 3, \& 6 for HLA-identical donor transplants and Days 1, 3, 6, \& 11 for MUD \& 9/10 related donor transplants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: 15mg/kg PO bid Day -2 to Day 60, then taper as tolerated (for MUD and 9/10 related donor transplants only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: target serum level is 5-10 ng/mL. Start with 0.03mg/kg PO bid Day -1 to Day 90, then taper thru Day 150 for HLA identical donor transplants and Day -1 to Day 180 then taper for MUD and 9/10 related donor transplants

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic cell transplantation
Description: 2,000,000-8,000,000 CD34+ cells total via infusion Days 0 and 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol
Description: 300 mg/day PO Days -8 thru -1
Study: NCT04009525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan（4 mg/kg/day,4 days）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan（4 mg/kg/day,4 days）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan（4 mg/kg/day,4 days）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide（50 mg/kg/day,4 days）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide（50 mg/kg/day,4 days）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide（50 mg/kg/day,4 days）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine（50 mg/m2/day,3 days）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine（50 mg/m2/day,3 days）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine（50 mg/m2/day,3 days）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Thymoglobulin（2.5 mg/kg/day,4 days）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Thymoglobulin（2.5 mg/kg/day,4 days）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Thymoglobulin（2.5 mg/kg/day,4 days）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine A
Description: cyclosporine A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil（0.25g/day）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil（0.25g/day）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil（0.25g/day）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate
Study: NCT00595920

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tovaxin
Description: 2 mL subcutaneous injections administered by a healthcare provider at weeks 0, 4, 8, 12, and 24 every year as required.
Study: NCT01877642

Intervention type: DRUG
Group type: OTHER
Intervention: Lorazepam 1 mg IM
Description: Lorazepam 1 mg intramuscular
Study: NCT04390139

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration on top of the standard administered treatment
Study: NCT01877642

Intervention type: DRUG
Group type: OTHER
Intervention: Lorazepam 1 mg IM
Description: Lorazepam 1 mg intramuscular

Intervention type: DRUG
Group type: OTHER
Intervention: Lorazepam 1 mg IM
Description: Lorazepam 1 mg intramuscular

Intervention type: DRUG
Group type: OTHER
Intervention: Lorazepam 1 mg IM
Description: Lorazepam 1 mg intramuscular

Intervention type: DRUG
Group type: OTHER
Intervention: Lorazepam 1 mg IM
Description: Lorazepam 1 mg intramuscular

Intervention type: DRUG
Group type: OTHER
Intervention: Lorazepam 1 mg IM
Description: Lorazepam 1 mg intramuscular

Intervention type: DRUG
Group type: OTHER
Intervention: Lorazepam 1 mg IM
Description: Lorazepam 1 mg intramuscular

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled loxapine 10 mg
Description: Inhaled Staccato loxapine 10 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled loxapine 10 mg
Description: Inhaled Staccato loxapine 10 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled loxapine 10 mg
Description: Inhaled Staccato loxapine 10 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled loxapine 10 mg
Description: Inhaled Staccato loxapine 10 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled loxapine 10 mg
Description: Inhaled Staccato loxapine 10 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled loxapine 10 mg
Description: Inhaled Staccato loxapine 10 mg
Study: NCT04434859

Intervention type: OTHER
Intervention: No intervention
Description: No intervention